FROM SCHIZOPHRENIA TO DEPRESSION: CLINICAL INSIGHTS INTO ARIPIPRAZOLE
Faculty:
L. Austin Fredrickson, MD, FACP
L. Austin Fredrickson is an Associate Professor of Internal Medicine at Northeast Ohio Medical University, where he serves as core faculty and teaches diagnostics, therapeutics, clinical skills, and health humanities. He is board-certified in general internal medicine and practices rural primary care.
Sandra Rogers, MD
Sandra Rogers, MD, is a primary care physician in Texas. She is board-certified through the American Board of Family Medicine and the American Board of Internal Medicine.
Anna Shurtleff Smith, MPH, BSN-RN
Anna Shurtleff Smith is a graduate of the University of North Texas Health Science Center, School of Public Health, with a community health focus, and Texas Tech University School of Nursing. She has clinical experience in both inpatient and outpatient settings. Anna is passionate about patient education, health literacy, and health communications.
Jennifer Salvon, RPh
Jennifer Salvon, RPh, is a clinical pharmacist at Mercy Medical Center and a freelance medical writer at Salvon Scientific in Massachusetts. Her career includes practice in hospital, retail, managed care, academic, and clinical research settings. As a lifelong learner, Jen enjoys researching and writing to educate herself and others.
Pamela Sardo, PharmD, BS
Pamela Sardo, PharmD, BS, is a freelance medical writer and licensed pharmacist. She is the founder and principal at Sardo Solutions in Texas. Pam received her BS from the University of Connecticut and her PharmD from the University of Rhode Island. Pam’s career spans many years in retail, clinics, hospitals, long-term care, Veterans Affairs, and managed health care responsibilities across a broad range of therapeutic classes and disease states.
Abstract
Aripiprazole is an atypical, second-generation antipsychotic indicated for the treatment of schizophrenia, bipolar disorder, and treatment-resistant major depressive disorder. It is also used to manage irritability associated with autistic disorder and treat Tourette syndrome. Studies have shown that aripiprazole is associated with a lower risk of several adverse effects compared to other antipsychotic medications. Long-acting injectable formulations play an important role in treatment and patient adherence.
Accreditation Statements
In support of improving patient care, RxCe.com LLC is jointly accredited by the Accreditation CouncilTM for Continuing Medical Education (ACCME®), the Accreditation Council for Pharmacy Education (ACPE®), and the American Nurses Credentialing Center (ANCC®), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 3 Interprofessional Continuing Education (IPCE) credits for learning and change.
Joint Universal Activity Number: The Joint Accreditation Universal Activity Numbers assigned to this activity are as follows:
Pharmacists: JA4008424-0000-26-023-H01-P
Pharmacy Technicians: JA4008424-0000-26-023-H01-T
Credits: 3 contact hour(s) (0.3 CEU(s)) of continuing education credit.
Credit Types:
IPCE Credits - 3 Credits
AAPA Category 1 Credit™️ - 3 Credits
AMA PRA Category 1 Credit™️ - 3 Credits
Pharmacy - 3 Credits
Type of Activity: Application
Media: Computer-Based Training (i.e., online courses)
Estimated time to complete activity: 3 contact hour(s) (0.3 CEU(s)), including Course Test and course evaluation.
Release Date: March 6, 2026 Expiration Date: March 6, 2029
Target Audience: This educational activity is for Physicians, Physician Assistants, Pharmacists, and Pharmacy Technicians
How to Earn Credit: From March 6, 2026, through March 6, 2029, participants must:
Read the “learning objectives” and “author and planning team disclosures;”
Take the “Educational Activity Pre-Test;”
Study the section entitled “Educational Activity;” and
Complete the Educational Activity Post-Test and Activity Evaluation. The Educational Activity Post-Test will be graded automatically. Following successful completion of the Educational Activity Post-Test with a score of 70% or higher, a statement of participation will be made available immediately. (No partial credit will be given.)
CME Credit: Credit for this course will be uploaded to CPE Monitor® for pharmacists. Physicians may receive AMA PRA Category 1 Credit™️ and use these credits toward Maintenance of Certification (MOC) requirements. Physician Assistants may earn AAPA Category 1 CME credit, reportable through PA Portfolio. All learners shall verify their individual licensing board’s specific requirements and eligibility criteria.
Statement of Need
Mental health disorders such as schizophrenia, bipolar disorder, major depressive disorder, autism-related irritability, and Tourette’s syndrome frequently require long-term pharmacotherapy. Many patients, however, experience suboptimal outcomes due to adverse effects, complex regimens, and poor adherence. Healthcare professionals from multiple disciplines must stay up to date on the pharmacology and FDA-approved indications of treatments such as aripiprazole. It is a third-generation antipsychotic with unique partial agonist activity for individualized treatment planning. Gaps persist regarding appropriate product selection. Contributory factors include the availability of numerous oral and long-acting injectable formulations, dosing, and conversion strategies. It is important to recognize and manage adverse effects, boxed warnings, and drug interactions. Inadequate patient education and limited use of adherence support strategies contribute to relapse, hospitalization, and reduced quality of life. This activity aims to address these gaps by strengthening the ability to select, monitor, and support treatment across diverse populations.
Learning Objectives: Upon completion of this educational activity, participants should be able to:
Review aripiprazole’s mechanism of action and approved indications
Describe recommended dosing and available dose forms of aripiprazole
Recognize warnings, contraindications, adverse effects, and drug interactions associated with aripiprazole
Discuss strategies to promote patient adherence to aripiprazole therapy
Disclosures
The following individuals were involved in developing this activity: L. Austin Fredrickson, MD, FACP; Sandra Rogers, MD; Anna Shurtleff Smith, MPH, BSN-RN; Jennifer Salvon, RPh; and Pamela Sardo, PharmD, BS. None of these individuals has a conflict of interest or financial relationship regarding the development of this activity. There are no financial relationships or commercial or financial support relevant to this activity to report or disclose by RxCe.com or any of the individuals involved in the development of this activity.
© RxCe.com LLC 2026: All rights reserved. No reproduction of all or part of any content herein is allowed without the prior, written permission of RxCe.com LLC.
Educational Activity Pre-Test
Which of the following describes initiation of oral aripiprazole therapy?
Start with long-acting injectable aripiprazole, then transition to oral administration
Start with the targeted daily dose
Start with oral aripiprazole to establish the patient’s tolerability to the drug
Start with the highest recommended dose and titrate down as needed
Which of the following describes the conversion from oral to long-acting injectable (LAI) formulations?
Injectable formulation dosing is the same as oral dosing
Initiate LAI therapy and stop oral therapy immediately
Initiate LAI therapy after stopping the oral therapy for 2 weeks
After the first LAI therapy, oral therapy should continue for 14 days
What is important to emphasize when counseling patients taking aripiprazole?
Weight gain may occur, although generally less pronounced than with other antipsychotics
Only children are at risk of extrapyramidal symptoms
Take aripiprazole with a high-fat meal
Store all products in the refrigerator
Educational Activity
From Schizophrenia to Depression: Clinical Insights into Prescribing Aripiprazole
Introduction
The understanding of mental health disorders has evolved over the centuries from supernatural beliefs to science-based medicine. Early societies attributed mental illness to divine forces and demon possession, treating it with rituals and exorcisms.1 The Greek physician Hippocrates shifted the view to natural, biological phenomena.1 Nevertheless, mental illnesses have often been associated with stigma and social judgment.1
Chlorpromazine’s discovery in 1950 marked the beginning of modern antipsychotics. This discovery prompted the subsequent discovery and development of haloperidol and fluphenazine, which block dopamine receptors but cause extrapyramidal adverse effects (EPS) such as tremor, stiffness, and balance problems.2
The advent of second-generation, or atypical, antipsychotic medications, including risperidone, olanzapine, quetiapine, and ziprasidone, represented a significant advancement by integrating dopamine and serotonin receptor modulation to mitigate movement disorders. While these agents have improved patient quality of life, they are associated with notable metabolic risks, including weight gain, diabetes mellitus, and dyslipidemia.2
Third-generation antipsychotics balance dopaminergic activity better, reducing adverse effects and improving cognitive and affective symptoms. Aripiprazole is the first third-generation antipsychotic to receive FDA approval.2 Approved in 2002, Aripiprazole is a partial dopamine D2 agonist used for schizophrenia, bipolar disorder, adjunctive therapy for major depressive disorder, and autism-related irritability.3,4 The original patent expired in 2014, leading to generic availability from 2015 onward.4 The development of long-acting injectable (LAI) formulations aims to improve treatment adherence, reduce relapse rates, and maintain more consistent symptom control than daily oral medication.
Pharmacology
Mechanism of Action
Aripiprazole’s mechanism of action centers on its activity as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and as an antagonist at serotonin 5-HT2A receptors.5 This unique profile allows aripiprazole to modulate the overactivity of dopamine (thought to cause positive symptoms in schizophrenia), while preserving dopamine signaling in pathways associated with movement and endocrine function.5,6
Aripiprazole acts as a partial agonist at D2 dopamine receptors.5,7 In regions of high dopamine (e.g., mesolimbic pathway), it acts functionally as an antagonist, reducing excessive dopamine activity that contributes to psychosis. In areas of low dopamine (e.g., mesocortical pathway), aripiprazole's partial agonism can provide a modest stimulatory effect, potentially improving negative and cognitive symptoms of schizophrenia.5
Aripiprazole is also a partial agonist at 5-HT1A receptors, which may help with mood and anxiety, and an antagonist at 5-HT2A receptors, which contributes to antipsychotic and antidepressant effects. Because of its partial agonist property at D2 receptors, aripiprazole has a lower risk of causing extrapyramidal adverse effects (like rigid muscles, tremors) compared to typical antipsychotics, as it only partially blocks dopamine rather than completely inhibiting it.5,7
Pharmacokinetics
Aripiprazole is available in several oral and long-acting injectable (LAI) formulations. After oral administration, aripiprazole is rapidly and well absorbed, with peak plasma concentrations achieved within 3 to 5 hours.​ The absolute oral bioavailability of the tablet formulation is approximately 87%, and food does not significantly affect absorption.​8
Aripiprazole exhibits a wide distribution throughout the body, with a volume of distribution of approximately 404 liters (about 4.9 L/kg), indicating extensive extravascular distribution.​ Aripiprazole and its active metabolite, dehydro-aripiprazole, are both highly bound to serum proteins (>99%, primarily to albumin). Aripiprazole metabolization occurs in the liver through dehydrogenation, hydroxylation, and N-dealkylation.​ The key enzymes responsible are CYP2D6 and CYP3A4.8
​Elimination is predominantly hepatic, with negligible renal clearance. The mean elimination half-life is approximately 75 hours for aripiprazole and 94 hours for dehydro-aripiprazole.​ Aripiprazole reaches steady-state concentrations after 14 days of repeated dosing.8
Long-acting injectable aripiprazole formulations differ from oral formulations in terms of absorption rate, time to steady state, and duration of effect. Depot release prolongs absorption. Aripiprazole monohydrate (AOM) reaches peak concentration 4–7 days post-injection and exhibits “flip-flop” kinetics, where absorption rate determines duration of action rather than elimination rate.5,9,10 AOM's elimination half-life is 30 to 46.5 days, and the 2-month ready-to-use formulation maintains therapeutic plasma concentrations for up to 60 days.9,10
Also available as an LAI, aripiprazole lauroxil is a prodrug converted to aripiprazole after absorption. After injection, the drug releases gradually over 30 to 60 days, reaching therapeutic levels 4 to 7 days after concurrent oral or injectable supplementation.39
Aripiprazole treatment needs to be tailored to each patient. Therapy initiation begins with oral formulations, then switches to an LAI. Knowledge of dose adjustment timing, product dosing, and schedules is important. Note that adverse effects may last longer with long-acting preparations.5
Indications
Aripiprazole has a range of FDA-approved indications, supported by multiple large, randomized, controlled trials that demonstrate its efficacy and safety. Table 1 lists the approved indications and corresponding clinical evidence.
Table 1
Aripiprazole Approved Indications11-35
| Indication | Clinical Evidence |
|---|---|
| Autism Spectrum Disorder (Irritability) in children aged 10 to 17 years | Two large, double-blind, randomized, placebo-controlled trials in children and adolescents with autism demonstrated that aripiprazole significantly reduced irritability, hyperactivity, and stereotypic behaviors compared with placebo, as measured by the Aberrant Behavior Checklist (ABC) and the Clinical Global Impressions scale. Short-term response rates ranged from 56% to 67% across studies, with a favorable safety profile. |
| Bipolar I Disorder in adults and children aged 10-17 years | Placebo-controlled trials in adults and children showed aripiprazole is effective for treating acute manic and mixed episodes, as well as for maintenance therapy. Clinical endpoints included reductions in the Young Mania Rating Scale (YMRS) and lower relapse rates. Both oral and long-acting injectable forms were proven effective and well-tolerated in bipolar I management. |
| Major Depressive Disorder (Adjunct) in adults | Four major placebo-controlled trials assessed aripiprazole as adjunct therapy in adults with major depressive disorder. Results showed that when aripiprazole was added to antidepressants, response rates (as measured by standard depression scales) were significantly improved compared to placebo, though adverse effects such as akathisia were more common |
| Schizophrenia in adults and children aged 13-17 years | Pivotal phase 3 randomized, double-blind, placebo-controlled trials established aripiprazole’s efficacy in adults and adolescents with schizophrenia. In a 12-week study of adults, aripiprazole showed significant reductions in Positive and Negative Syndrome Scale (PANSS) scores compared with placebo, indicating symptom improvement. Long-acting injectable formulations also demonstrated maintenance of therapeutic benefit and reduced relapse risk in patients with chronic conditions. |
| Tourette’s Syndrome in children aged 6 to 18 years | Randomized, double-blind, placebo-controlled studies in children and adolescents with Tourette’s disorder demonstrated that aripiprazole reduced tic severity compared to placebo. Trials used standard tic rating scales and showed that aripiprazole was generally well tolerated and effective, leading to its recommendation and approval for this indication. |
Off-label uses
Aripiprazole is widely used off-label for psychiatric conditions like treatment-resistant obsessive-compulsive disorder (OCD), borderline personality disorder, anxiety disorders, post-traumatic stress disorder (PTSD), tics beyond Tourette's, and agitation or psychosis in dementia.36-38 Evidence for these uses relies on small studies and case series. With tics beyond Tourette's, if tics are transient, mild and non-disabling, a watchful waiting approach may be recommended, as they may resolve spontaneously.37 Benefits for OCD and borderline personality disorder are modest, and there is a lack of support for anxiety, PTSD, substance use disorders, and ADHD is limited or lacking. Due to increased mortality risk in elderly patients and generally inconclusive data, its off-label use should be carefully considered.36
Dosing and Administration
Dosing
Aripiprazole is available in a wide range of oral and injectable doses and formulations. Table 2 lists available aripiprazole dose forms and storage requirements.
Table 2
Aripiprazole Available Dose Forms and Storage Requirements39-44
| Dose Form | Strength(s) | Administration Notes | Storage Requirements |
|---|---|---|---|
| Oral | |||
| Tablets | 2, 5, 10, 15, 20, and 30 mg | Take with or without food | Store at 25°C (77°F) Excursions permitted to 15°C to 30°C (59°F to 86°F) Use the oral solution within 6 months after opening Do not store in humid conditions |
| Disintegrating tablet | 10 and 15 mg | Place on the tongue immediately after package removal Do not push through foil Take with or without liquids | |
| Oral solution | 1 mg/ml (150 ml bottle) | Shake gently | |
| Tablet with a sensor | 2, 5, 10, 15, 20, and 30 mg | Swallow whole; do not divide, crush, or chew May be taken with or without food | Store at 20°C to 25°C (68°F to 77°F) Excursions permitted to 15°C to 30°C (59°F to 86°F) Do not store in humid conditions Store wearable sensor between 15°C to 30°C (59°F to 86°F) Can be stored in 15% to 93% relative humidity |
| |||
| Aripiprazole monohydrate prefilled ER syringe (Abilify Maintena®) | 300 and 400 mg | Administer IM once per calendar month (not every 4 weeks) Do not administer IV or SC Rotate injection sites | Store below 30°C (86°F) Do not freeze Protect from light and store in the original package |
| Aripiprazole monohydrate powder for suspension (Abilify Maintena®) | 300 and 400 mg | Store unused vials at 77°F Excursions permitted to 59°F to 86°F If not immediately used after reconstitution, store at room temperature in the vial Do not store in a syringe | |
| Aripiprazole monohydrate prefilled syringe (Abilify Asimtufii®) | 720 mg/2.4 ml 960 mg/3.2 ml | Administer every 2 months into the gluteal muscle only | Store at 25°C (77°F) Excursions permitted to 15°C to 30°C (59°F to 86°F) |
| Aripiprazole lauroxil prefilled syringe (Aristada®) | 441 mg/1.6 mL 662 mg/2.4 mL 882 mg/3.2 mL 1064 mg/3.9 mL | Administer IM in either the deltoid or the gluteal muscle Monthly: 441 mg, 662 mg, and 882 mg Every 6 weeks: 882 mg Every 2 months: 1064 mg | Store at 20°C to 25°C (68°F to 77°F) Excursions permitted to 15°C to 30°C (59°F to 86°F) |
| Aripiprazole lauroxil prefilled syringe (Aristada Initio®) | 675 mg/2.4 mL | Administer IM in either the deltoid or the gluteal muscle | |
Aripiprazole is available in a unique oral digital medicine product combining aripiprazole with an ingestible sensor to track medication ingestion. Indications include use in adults with schizophrenia, bipolar I disorder, and as an adjunctive treatment for major depressive disorder.​44
The oral digital medicine product works as follows:44
It consists of an aripiprazole tablet embedded with a small ingestible event marker (IEM) sensor.
Sensor activation occurs upon ingestion and sends a signal to a wearable patch placed on the patient's abdomen.
A patch then communicates data to a smartphone application, allowing patients, healthcare providers, and caregivers to track medication ingestion, activity levels, and self-reported mood/rest.​
Web-based portals that provide healthcare providers and caregivers with a summary of ingestion over time.​
Before initiating therapy, patients must demonstrate willingness and capability to use the system's smartphone app, wearable patch, and portal.​ The system provides an objective summary for collaborative treatment, not a substitute for professional clinical judgment and expertise.​ Safety warnings include those associated with aripiprazole. This product, available from specialty pharmacies, is a unique approach that combines medication with digital tracking to facilitate the monitoring of oral medication adherence.
Administration
Initiation of aripiprazole therapy begins with oral administration to establish tolerability before considering long-acting injectable forms. Depending on the indication, the oral dose for adults ranges from 10 to 30 mg daily. In clinical practice, both tablet and liquid forms are used; injectables are reserved for long-term management, especially where medication adherence is a concern.​ Tailoring the LAI dose is based on previous oral tolerance and response, and it is initiated only after establishing oral tolerability. Table 3 lists oral dosing for aripiprazole.​
Table 3
Aripiprazole Oral Dosing Recommendations39-44
| Indication | Parameters | Initial Dose | Titration | Max Dose |
|---|---|---|---|---|
| Autism Spectrum Disorder (Irritability) | Children 10 to 17 years | 2 mg once daily | 5 mg daily at 1-week intervals | 15 mg daily |
| Bipolar I Disorder | Adults | 10 to 15 mg once daily | 5 to 10 mg daily at 1-week intervals | 30 mg daily |
| Children 10 to 17 years | 2 mg daily | Increase to 5 mg daily after 2 days Increase to 10 mg daily after 2 additional days | 30 mg daily | |
| Major Depressive Disorder (Adjunct) | Adults | 2 to 5 mg once daily | 5 mg daily at 1-week intervals | 15 mg daily |
| Schizophrenia | Adults | 10 to 15 mg once daily | 5 mg daily increments at 2-week intervals | 30 mg daily |
| Children 13 to 17 years | 2 mg once daily | Increase to 5 mg daily after 2 days Increase to 10 mg daily after 2 additional days May continue 5 mg daily at 2-week intervals | 30 mg daily | |
| Tourette’s Syndrome | Weight of 50 kg or more | 2 mg once daily | Increase to 5 mg daily after 2 days Increase to 10 mg daily after 5 additional days May continue 5 mg daily at 2-week intervals | 20 mg daily |
| Weight less than 50 kg | 2 mg once daily | Increase to 5 mg daily after 2 days Increase gradually at 1-week intervals | 10 mg daily |
Note: No dose adjustments necessary in renal or hepatic impairment
Conversion from oral aripiprazole to LAI requires careful planning to ensure continued therapeutic drug levels and minimize relapse risk. Differences in dosing interval, product formulation, initiation requirements, clinical indications, and patient preferences guide selection between available aripiprazole LAIs.
The different LAI products have distinct approved indications. All LAIs are approved for the treatment of schizophrenia in adults.4,39,45 Aripiprazole and aripiprazole monohydrate carry indications for maintenance monotherapy of bipolar I disorder in adults. None of the available LAIs are approved for use in pediatric patients.4,39,45
The standard approach is stabilizing the patient on oral aripiprazole for at least 14 days before switching to the LAI. After the first LAI injection, oral aripiprazole should usually be continued for 14 additional days to maintain therapeutic plasma levels during the transition period.5
Aripiprazole lauroxil offers a 21-day oral overlap or a single-dose initiation method (SDIAL), providing conversion coverage without the need for prolonged oral use. SDIAL involves administering a one-time 675 mg aripiprazole lauroxil IM injection, a single 30 mg oral aripiprazole dose, and the first maintenance dose either on the same day or up to 10 days later. This strategy rapidly achieves therapeutic levels and enables immediate initiation of long-acting therapy for schizophrenia.6,41
Patients switching from other antipsychotics require oral aripiprazole stabilization before LAI conversion. All LAIs require intramuscular (IM) route administration, never intravenously or subcutaneously. Observe for early signs of relapse during the transition, especially when decreasing the concomitant oral dose.
Table 4
Oral-to-LAI Aripiprazole Conversion39-42
| Oral dose | 10 mg daily | 15 mg daily | 20 mg or more daily |
|---|---|---|---|
Aripiprazole monohydrate, monthly (Abilify Maintena®) | 300 mg | 400 mg | 400 mg |
Aripiprazole monohydrate, every 2 months Abilify Asimtufii®) | N/A | 960 mg | N/A |
Aripiprazole lauroxil monthly (Aristada®) | 441 mg | 662 mg | 882 mg |
Aripiprazole lauroxil, every 6 weeks (Aristada®) | N/A | 882 mg | N/A |
Aripiprazole lauroxil, every 2 months (Aristada®) | N/A | 1064 mg | N/A |
Safety Profile
Common adverse effects include tremors, headaches, dizziness, nausea, vomiting, constipation, sleep disturbances, increased salivation, blurred vision, and changes in appetite. Weight gain, although generally less pronounced than with other antipsychotics, and metabolic changes, such as increased blood sugar or lipid levels, may occur.39-44 Extrapyramidal symptoms are a more serious adverse effect. blood sugar or lipid levels, may occur.37-42
Movement issues that include the following:39-44
Drug-induced Parkinsonism: stiffness and tremors
Akathisia: restlessness and the inability to sit still
Acute Dystonia: sudden muscle spasms
Tardive dyskinesia: Involuntary facial and mouth movements
Aripiprazole use may cause seizures, orthostatic hypotension, hyperprolactinemia, and rare conditions like neuroleptic malignant syndrome and agranulocytosis. Regular monitoring of metabolic, neurologic, and cardiovascular parameters is recommended, particularly during dosage changes or initiation of therapy.
Aripiprazole should not be used by individuals who have a documented hypersensitivity to aripiprazole or its components. It is essential to avoid aripiprazole in elderly patients with dementia-related psychosis due to an increased risk of cerebrovascular events and death.39-44
In addition, patients with cardiovascular disease, diabetes, seizure disorders, or a previous history of neuroleptic malignant syndrome or blood clots should use aripiprazole with caution. Manufacturer information includes a boxed warning for increased risk of suicidal thoughts and actions, particularly in children, adolescents, and young adults. Aripiprazole carries warnings about the potential development of impulse control disorders, such as compulsive gambling, shopping, eating, and sexual activity.39-44
Drug Interactions
Many potential drug-drug interactions with aripiprazole exist. Common interactions involve drugs that inhibit or induce enzymes that metabolize aripiprazole, particularly CYP3A4 and CYP2D6. These interactions may alter the effectiveness of aripiprazole or increase its adverse effects.7
Inhibition of CYP2D6 raises aripiprazole blood levels and increases the risk of adverse effects. Certain antidepressants, including fluoxetine and paroxetine, inhibit CYP2D6. Concomitant use with aripiprazole may necessitate dose adjustments.7
Similarly, CYP2D6 inhibition slows metabolism, increasing aripiprazole concentrations and raising the risk of adverse effects such as dizziness, drowsiness, and low blood pressure.7
Induction of these enzymes may lower aripiprazole concentrations and reduce its therapeutic effects. Examples include seizure drugs (e.g., carbamazepine, phenytoin) and the antibiotic rifampin. Another significant interaction is with benzodiazepines, which can amplify sedative effects and orthostatic hypotension.7
Healthcare providers must monitor for these interactions and adjust therapy to ensure patient safety. Before initiating aripiprazole, a careful review of current medications is necessary. Patients should be advised to report any new medications and consult their pharmacist or prescriber before starting or stopping therapies that might interact with aripiprazole.​
Look-Alike/Sound-Alike Concerns
Look-alike and sound-alike (LASA) drug names are a significant cause of medication errors across all healthcare settings.46 These errors occur when drug names or packaging appear similar, leading to prescribing, dispensing, or administration errors that can cause patient harm. The Institute for Safe Medication Practices (ISMP) is a nonprofit organization dedicated to preventing medication errors and promoting safe medication practices. Aripiprazole is recognized by the Institute for Safe Medication Practices (ISMP) and the FDA as a LASA medication. The most frequently documented confusion occurs between aripiprazole and rabeprazole, a proton pump inhibitor used for acid-related disorders.46
Patient Case
Mr. A. is a 60-year-old man with a history of bipolar II disorder.47 He was followed in an outpatient practice. He had no prior history of substance use disorder, psychiatric hospitalizations, or suicide attempts. He was stable for 6+ months on lamotrigine 300 mg daily, venlafaxine 75 mg daily, risperidone 1.5 mg twice daily, and clonazepam 1 mg twice daily as needed. During a follow-up appointment, he displayed moderate grandiose delusions. What is a possible treatment decision?
The physician prescribed a risperidone cross-taper with initiation of aripiprazole to address those symptoms. A month later, Mr. A. presented with an elated mood. No adverse effects were noted. Aripiprazole was increased to 15 mg daily. Risperidone was completely tapered off, and his symptoms disappeared. What is a reasonable time period to ask the patient to return for follow-up?
After a month of treatment with aripiprazole, Mr. A. became obsessed with engaging in sexual activities and had a very high libido and an uncontrollable urge to masturbate. What are the next steps for the physician to consider?
A complete medical workup was performed, and all of his laboratory values (including thyroid function and HIV) came back within normal limits. His head computed tomography scan was unchanged from prior scans. Aripiprazole was ultimately discontinued, and all of his hypersexuality symptoms ceased within a few days. After 2 weeks, Mr. A. was at his baseline level of functioning prior to the cross-taper when he was asymptomatic. What is a possible mechanism for the patient’s adverse effect?
Many antipsychotics cause decreased libido and reduce sexual desire and function. This activity describes that aripiprazole acts as a partial agonist at the dopamine D2 receptor and the 5-HT1A receptor, and as an antagonist at the 5-HT2A receptor. Publications reveal that partial dopaminergic agonistic activity can cause compulsive behaviors, such as gambling or hypersexuality, at rates of 6% to 24%.
Special Populations
Pregnancy and Lactation
Aripiprazole is frequently used in women of childbearing age due to its safety and efficacy.48 Animal studies show potential fetal risks, making it essential to assess the risks and benefits of use during pregnancy. While there are no randomized controlled trials in pregnant humans, available animal and exposure data suggest similar risk levels to other antipsychotics.48-51 Use of antipsychotics in late pregnancy has been linked to extrapyramidal and withdrawal symptoms in newborns. The American College of Obstetricians and Gynecologists (ACOG) recommends that a multidisciplinary team, including obstetrics, mental health, primary care, and pediatrics, manage psychiatric medication use during pregnancy.52
Aripiprazole and dehydro-aripiprazole are present in breast milk. Breastfeeding is considered safe if the relative infant dose (RID) is below 10%. For aripiprazole, the RID ranges from 0.7% to 8.3%.53 Infants should be monitored for drowsiness, lethargy, or developmental delays. Clinicians need to carefully weigh the risks and benefits of breastfeeding while on Aripiprazole.
Pediatrics
Aripiprazole use in children and adolescents comes with several specific concerns, most notably regarding increased risks for certain adverse effects and the need for close monitoring. Children and teens are more likely than adults to experience weight gain, drowsiness, metabolic changes, and extrapyramidal symptoms (tremors, restlessness, involuntary movements) when using aripiprazole.54 Adverse effects like fatigue, nausea, increased appetite, and sometimes drooling or tremor tend to be more pronounced and appear sooner in younger patients.55
Geriatrics
Initiate aripiprazole at low doses in geriatric patients and titrate the dose slowly, with close monitoring. In older adults, be aware of risks such as hyponatremia and syndrome of inappropriate antidiuretic hormone (SIADH).56 Sodium levels should be checked when starting or adjusting the aripiprazole therapy. Reduce other CNS depressants and implement fall prevention strategies if treatment is required.56 Antipsychotics should be avoided in geriatric patients for dementia-related psychosis due to increased morbidity and mortality.56
Importance of Adherence
Adherence to aripiprazole therapy is crucial for achieving symptom stability and preventing relapse in conditions such as schizophrenia and bipolar disorder. Still, it is a persistent challenge due to various patient, treatment, and system-related factors.57 Nonadherence can significantly compromise clinical outcomes, leading to increased hospitalization, relapse, lower quality of life, and the development of treatment resistance.57
Consistent adherence to aripiprazole is essential for maintaining symptom control and preventing recurrence or exacerbation of psychiatric illness. Nonadherence raises the risk for acute episodes, increased suicide risk, emergency services usage, arrests, and reduced functional capacity.57 Persistent gaps in medication raise the likelihood of relapse, often requiring acute care and leading to a reduction in overall brain volume and cognitive function.57 Long-acting injectable (LAI) formulations of aripiprazole have been shown to improve adherence for some patients by reducing dosing frequency and increasing physician contact.58
Common issues affecting adherence include the following:57
Negative attitudes toward medication, poor insight into illness, and stigma around psychiatric treatment are major barriers to continuous adherence.
Distressing adverse effects, such as movement disorders, weight gain, and sedation, decrease motivation to maintain therapy.
Substance use disorder, younger age, homelessness, lack of social support, and co-occurring psychiatric conditions further reduce adherence rates.
Cognitive impairment and poor therapeutic alliance with care providers also contribute to intentional or unintentional nonadherence.
Withdrawal symptoms and fear of adverse effects when stopping medication sometimes lead to incomplete or abrupt discontinuation.
Early identification of nonadherence and a personalized, patient-centered approach to selecting antipsychotic treatment optimizes outcomes. Education and counseling on the importance of continued medication use, monitoring for adverse effects, and improving insight into the illness are recommended. Family and social support networks can help reinforce adherence and provide additional reminders for taking medication.
The effectiveness of aripiprazole therapy relies heavily on sustained patient adherence, with multiple clinical, behavioral, and social factors influencing outcomes. Addressing these issues requires individually tailored strategies, proactive monitoring, and robust support systems to minimize the risk of relapse and enhance long-term stability.
Aripiprazole adverse effects are a common reason for therapy discontinuation. Adverse effect management involves supportive measures for common adverse effects and urgent interventions for serious and life-threatening reactions.​
Table 6
Adverse Effect Management Strategies39,59,60
| Adverse Effect | Strategy |
|---|---|
| Insomnia | Consider switching to morning dosing, avoiding stimulants and screens before bed, and using good sleep hygiene. If sleep does not improve, consult a healthcare professional. |
| Fatigue | The patient should avoid driving or hazardous activities. |
| Akathisia or Restlessness | Dose reduction or the addition of a beta-blocker or benzodiazepine may help; consult the prescriber for persistent symptoms. |
| Headache | Rest, hydration, and, if necessary, OTC analgesics (e.g., acetaminophen). Medical consultation if persistent or severe.​ |
| Dizziness | Avoid getting overheated or dehydrated.39 Do not over-exercise. In hot weather, stay inside in a cool place if possible. Stay out of the sun. Do not wear too much or heavy clothing. Drink plenty of water.39 Lightheadedness or fainting may happen when rising too quickly from a sitting or lying position.39 |
| Nausea/Vomiting | Nursing staff should immediately notify the primary physician for further evaluation. Interventions include taking medication with food, eating bland meals, and sipping fluids to avoid dehydration. A medical evaluation is required in severe cases.​ |
| Weight Gain | Encourage lifestyle changes, including diet and exercise, and monitor metabolic parameters |
| Constipation | Use laxatives appropriately. If possible, have patients or family track bowel movements daily.60 |
Many of the adverse effects of aripiprazole can be prevented by collecting baseline assessments and labs. To increase adherence and early identification of adverse effects, involve caregivers and the interprofessional health team.​ Healthcare professionals can compare a patient’s baseline assessments and labs to identify potential contraindications to aripiprazole use. In adult patients, the following assessments and lab tests should be done:
Vitals: Electrocardiogram (EKG), Blood Pressure, Weight, Height, BMI, Waist circumference59
Labs: Comprehensive Metabolic Panel (CMP), Complete Blood Count (CBC), Liver Transaminase Levels (ALT and AST blood tests), Blood Urea Nitrogen (BUN), Creatinine, A1C (to measure patient’s average blood sugar levels)59
Screening: Abnormal Involuntary Movement Scale (AIMS) for extrapyramidal symptoms, Ocular exam,57 Suicide screening.39
In pediatric patients, the vitals and labs referenced in the adult section should be done, as well as the following:
Screening: Pediatric AIMS for extrapyramidal symptoms, Ocular exam,3 Youth ASQ, Suicide screening, in lieu of Adult Suicide Screening Tool.
Assessment Resources Adult Suicide Screening Tool: Ask Suicide-Screening Questions (ASQ) Toolkit may be found at the following link: https://www.nimh.nih.gov/research/research-conducted-at-nimh/asq-toolkit-materials Pediatric Suicide Screening Tool: Youth ASQ Toolkit may be found at the following link: https://www.nimh.nih.gov/research/research-conducted-at-nimh/asq-toolkit-materials/youth-asq-toolkit Pediatric: Abnormal Involuntary Movement Scale (AIMS) may be found at the following link: https://www.aacap.org/App_Themes/AACAP/docs/member_resources/toolbox_for_clinical_practice_and_outcomes/monitoring/AIMS.pdf |
|---|
If vitals are outside normal ranges, medical attention may be required, or aripiprazole may need to be discontinued. These include leukopenia and weight gain:
Leukopenia is a white blood count (WBC) < 4000/mcL (< 4 Ă— 109/L)61
Neutropenia is a blood neutrophil count of < 1500/mcL (< 1.5 Ă— 109/L) in White people and < 1200/mcL (< 1.2 Ă— 109/L) in Black people62
Weight gain of over 7%63
Any symptoms of severe reaction or rapidly worsening adverse effects require immediate medical attention and discontinuation of aripiprazole.
Patient Education
Patient education on aripiprazole should cover medication adherence, potential adverse effects, drug interactions, precautions, and what to monitor during treatment.
The following list contains key counseling points taken from Table 6 above, as well as other important information, for patients prescribed aripiprazole:
Take the medication exactly as prescribed every day. Do not stop or change the dose without consulting your healthcare provider, as sudden changes can worsen symptoms or cause adverse effects. Missing doses increases the risk of relapse in conditions like schizophrenia or bipolar disorder.
Be aware of possible adverse effects such as dizziness, lightheadedness, or fainting, especially when standing up quickly. To minimize this, rise slowly from lying or seated positions.
Watch for new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior such as agitation, nervousness, or restlessness. Report these promptly to your healthcare provider.
Avoid alcohol and CNS depressants (e.g., sedatives, sleeping pills, antihistamines) as these may enhance drowsiness or sedation.
Inform your healthcare provider about all other medications, supplements, or herbal products you are taking, especially allergy medications and St. John's wort, due to possible interactions.
Discuss any history or presence of heart disease, blood pressure irregularities, seizures, diabetes, or previous mental health medication adverse effects with your provider.
Regular monitoring of weight, blood sugar, cholesterol, and movement symptoms may be necessary as long-term aripiprazole use can affect metabolic parameters and cause movement disorders.
If pregnant or planning pregnancy, discuss the risks and benefits of treatment with your provider, as aripiprazole may have risks for the fetus, especially in the third trimester.
Be cautious when driving or operating machinery until you know how aripiprazole affects you due to potential dizziness or sedation.
Effective patient counseling on aripiprazole involves emphasizing medication adherence, alertness to mood changes or adverse effects, avoiding interacting with other drugs, monitoring health parameters, and seeking medical advice before any medication changes or pregnancy planning.
Summary
Aripiprazole is a third-generation antipsychotic medication approved for the treatment of schizophrenia, bipolar I disorder, major depressive disorder as adjunct therapy, autism spectrum disorder-related irritability, and Tourette’s syndrome. Its unique activity as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors, allows it to modulate neurotransmitter pathways, reducing psychotic symptoms with a lower risk of movement-related adverse effects compared to earlier antipsychotics. Aripiprazole is available in multiple oral and long-acting injectable forms, with dosing tailored to the patient’s indication, age, and clinical response.
Safety considerations include avoiding use in those with hypersensitivity to aripiprazole or its components, and in elderly patients with dementia-related psychosis due to increased risk of adverse events. Common adverse effects are tremor, dizziness, sleep disturbances, weight gain, and metabolic changes, while serious risks include extrapyramidal symptoms, seizures, and impulse control disorders. Aripiprazole interacts with various medications due to CYP2D6 and CYP3A4 metabolism, requiring careful review of concurrent drugs.
Special populations, such as pregnant or breastfeeding women, children, and older adults, require tailored dosing and monitoring. Patient adherence is critical for maintaining symptom control and preventing relapse, with LAIs offering improved adherence for some individuals. Education should emphasize consistent use, awareness of potential adverse effects and drug interactions, and regular monitoring of health parameters.
References
Leo DG. A Fragmented Mind: Altered States of Consciousness and Spirit Possession Between Rituals and Therapy. Integr Psychol Behav Sci. 2025;59(3):59. Published 2025 Jul 30. doi:10.1007/s12124-025-09929-0
Weston-Green K. Antipsychotic Drug Development: From Historical Evidence to Fresh Perspectives. Front Psychiatry. 2022;13:903156. Published 2022 Jun 16. doi:10.3389/fpsyt.2022.903156
Kikuchi T, Maeda K, Suzuki M, Hirose T, Futamura T, McQuade RD. Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole. Neuropsychopharmacol Rep. 2021;41(2):134-143. doi:10.1002/npr2.12180.
Casey AB, Canal CE. Classics in Chemical Neuroscience: Aripiprazole. ACS Chem Neurosci. 2017;8(6):1135-1146. doi:10.1021/acschemneuro.7b00087
Goldberg JF, Achtyes ED, Correll CU, Sajatovic M, Saklad SR. Published 2025 Jun 13. doi:10.4088/JCP.JCP.plunlai2424ah1inetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report. J Clin Psychiatry. 2025;86(2):plunlai2424ah1. Published 2025 Jun 13. doi:10.4088/JCP.plunlai2424ah1
Maini K, Gould H, Hicks J, et al. Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review. Neurol Int. 2021;13(3):279-296. Published 2021 Jul 1. doi:10.3390/neurolint13030029
Rapagnani MP. Safety, efficacy, and patient acceptability of aripiprazole in the maintenance treatment of bipolar disorder. Clinical Medicine Insights: Therapeutics. 2012;4:131–44. 10.4137/CMT.S7388
Abilify (aripiprazole). Package Insert. Otsuka America Pharmaceutical, Inc.: 2014. Accessed October 20, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021436s038,021713s030,021729s022,021866s023lbl.pdf
Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. CNS Drugs. 2021;35(1):39-59. doi:10.1007/s40263-020-00779-5
Yáñez JA, Remsberg CM, Sayre CL, Forrest ML, Davies NM. Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development. Ther Deliv. 2011;2(5):643-672. doi:10.4155/tde.11.19
Hirsch LE, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2016;(6):CD009043. Published 2016 Jun 26. doi:10.1002/14651858.CD009043.pub3
Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110-1119. doi:10.1097/CHI.0b013e3181b76658
Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533-1540. doi:10.1542/peds.2008-3782
Lamy M, Erickson CA. Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders. Curr Probl Pediatr Adolesc Health Care. 2018;48(10):250-264. doi:10.1016/j.cppeds.2018.08.015
Marcus RN, Owen R, Manos G, et al. Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study. J Child Adolesc Psychopharmacol. 2011;21(3):229-236. doi:10.1089/cap.2009.0121
Quezada J, Coffman KA. Current Approaches and New Developments in the Pharmacological Management of Tourette Syndrome. CNS Drugs. 2018;32(1):33-45. doi:10.1007/s40263-017-0486-0
Sallee F, Kohegyi E, Zhao J, et al. Randomized, Double-Blind, Placebo-Controlled Trial Demonstrates the Efficacy and Safety of Oral Aripiprazole for the Treatment of Tourette's Disorder in Children and Adolescents. J Child Adolesc Psychopharmacol. 2017;27(9):771-781. doi:10.1089/cap.2016.0026
Yang C, Yi Q, Zhang L, Cui H, Mao J. Safety of aripiprazole for tics in children and adolescents: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(22):e15816. doi:10.1097/MD.0000000000015816
Li DJ, Tseng PT, Stubbs B, et al. Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2017;79(Pt B):289-301. doi:10.1016/j.pnpbp.2017.06.023
Brown R, Taylor MJ, Geddes J. Aripiprazole alone or in combination for acute mania. Cochrane Database Syst Rev. 2013;2013(12):CD005000. Published 2013 Dec 17. doi:10.1002/14651858.CD005000.pub2
Lindström L, Lindström E, Nilsson M, Höistad M. Maintenance therapy with second generation antipsychotics for bipolar disorder - A systematic review and meta-analysis. J Affect Disord. 2017;213:138-150. doi:10.1016/j.jad.2017.02.012
Vieta E, T'joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry. 2008;165(10):1316-1325. doi:10.1176/appi.ajp.2008.07101560
Torres-Llenza V, Lakshmin P, Lieberman DZ. Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients. Neuropsychiatr Dis Treat. 2018;14:285-292. Published 2018 Jan 11. doi:10.2147/NDT.S129559
Calabrese JR, Sanchez R, Jin N, et al. Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study. J Clin Psychiatry. 2017;78(3):324-331. doi:10.4088/JCP.16m11201
Kamijima K, Yasuda M, Yamamura K, Fukuta Y. Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder. Curr Med Res Opin. 2018;34(12):2105-2112. doi:10.1080/03007995.2018.1519317
Lenze EJ, Mulsant BH, Blumberger DM, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(10011):2404-2412. doi:10.1016/S0140-6736(15)00308-6
Nuñez NA, Joseph B, Pahwa M, et al. Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. J Affect Disord. 2022;302:385-400. doi:10.1016/j.jad.2021.12.134
Cheon EJ, Lee KH, Park YW, et al. Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study. J Clin Psychopharmacol. 2017;37(2):193-199. doi:10.1097/JCP.0000000000000663
Khanna P, Komossa K, Rummel-Kluge C, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013;(2):CD006569. Published 2013 Feb 28. doi:10.1002/14651858.CD006569.pub4
Correll CU, Kohegyi E, Zhao C, et al. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study. J Am Acad Child Adolesc Psychiatry. 2017;56(9):784-792. doi:10.1016/j.jaac.2017.06.013
Wang C, Shi W, Huang C, Zhu J, Huang W, Chen G. The efficacy, acceptability, and safety of five atypical antipsychotics in patients with first-episode drug-naĂŻve schizophrenia: a randomized comparative trial. Ann Gen Psychiatry. 2017;16:47. Published 2017 Dec 22. doi:10.1186/s12991-017-0170-2
Ribeiro ELA, de Mendonça Lima T, Vieira MEB, Storpirtis S, Aguiar PM. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. Eur J Clin Pharmacol. 2018;74(10):1215-1233. doi:10.1007/s00228-018-2498-1
Marcus SC, Zummo J, Pettit AR, Stoddard J, Doshi JA. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm. 2015;21(9):754-768
Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73(5):617-624. doi:10.4088/JCP.11m07530
Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(11):1254-1260. doi:10.4088/JCP.14m09168
Aripiprazole Indications: FDA-Approved and Off-Label Uses. Psychopharmacology Institute. Published March 20, 2024. https://psychopharmacologyinstitute.com/publication/aripiprazole-indications-fda-approved-and-off-label-uses-2120/
Monfrini E, Saleh C, Servello D, Jaszczuk P, Porta M. From Pharmacological Treatment to Neuromodulation: A Comprehensive Approach to Managing Gilles de la Tourette Syndrome. Int J Mol Sci. 2025;26(18):8831. Published 2025 Sep 10. doi:10.3390/ijms26188831
Cox JH, Seri S, Cavanna AE. Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders. Pediatric Health Med Ther. 2016;7:57-64. Published 2016 Jun 27. doi:10.2147/PHMT.S87121
ABILIFY- aripiprazole tablet. Prescribing Information. Otsuka America Pharmaceutical, Inc. Updated January 29, 2025. Accessed March 5, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c040bd1d-45b7-49f2-93ea-aed7220b30ac
ABILIFY MAINTENA- aripiprazole kit. Prescribing Information. Otsuka America Pharmaceutical, Inc. Updated April 15, 2025. Accessed March 5, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6
ARISTADA- aripiprazole lauroxil injection, suspension, extended release. Prescribing Information. Alkermes, Inc. Updated January 28, 2025. Accessed March 5, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17a8d11b-73b0-4833-a0b4-cf1ef85edefb
ARISTADA INITIO- aripiprazole lauroxil injection, suspension, extended release. Prescribing Information. Alkermes, Inc. Updated January 28, 2025. Accessed March 5, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18fdfd9-31cd-4a2f-9f1c-ebc70d7a9403
OPIPZA- aripiprazole film, soluble. Prescribing Information. Carwin Pharmaceutical Associates, LLC. Updated January 30, 2025. Accessed March 5, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b47ede68-8942-4432-af7e-57afc14b2ba4
ABILIFY MYCITE- aripiprazole tablet with sensor. Prescribing Information. Otsuka America Pharmaceutical, Inc. Updated January 31, 2025. Accessed March 5, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8787c3f-5e41-42d1-8091-44b56346620f
Tuplin EW, Holahan MR. Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity. Curr Neuropharmacol. 2017;15(8):1192-1207. doi:10.2174/1570159X15666170413115754
Institute for Safe Medication Practices (ISMP). ISMP List of Confused Drug Names. ISMP; 2024. Accessed October 20, 2025. https://online.ecri.org/hubfs/ISMP/Resources/ISMP_ConfusedDrugNames.pdf
Bulbena-Cabré A, Bulbena A. Aripiprazole-Induced Hypersexuality. Prim Care Companion CNS Disord. 2016;18(6). doi: 10.4088/PCC.16l01983
Cuomo A, Goracci A, Fagiolini A. Aripiprazole use during pregnancy, peripartum and lactation. A systematic literature search and review to inform clinical practice. J Affect Disord. 2018;228:229-237. doi:10.1016/j.jad.2017.12.021
Ennis ZN, Damkier P. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review. Basic Clin Pharmacol Toxicol. 2015;116(4):315-320. doi:10.1111/bcpt.12372
Huybrechts KF, Hernández-DĂaz S, Patorno E, et al. Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA Psychiatry. 2016;73(9):938-946. doi:10.1001/jamapsychiatry.2016.1520
Viswanathan M, Middleton JC, Stuebe AM, et al. Maternal, Fetal, and Child Outcomes of Mental Health Treatments in Women: A Meta-Analysis of Pharmacotherapy. Psychiatr Res Clin Pract. 2021;3(3):123-140. Published 2021 May 4. doi:10.1176/appi.prcp.20210001
Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol. 2009;114(3):703-713.[PubMed 19701065]
Hotham N, Hotham E. Drugs in breastfeeding [published correction appears in Aust Prescr. 2016 Feb;39(1):27]. Aust Prescr. 2015;38(5):156-159. doi:10.18773/austprescr.2015.056
Coustals N, MĂ©nard ML, Cohen D. Aripiprazole in Children and Adolescents. J Child Adolesc Psychopharmacol. 2021;31(1):4-32. doi:10.1089/cap.2020.0014
Mankoski R, Stockton G, Manos G, et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. J Child Adolesc Psychopharmacol. 2013;23(8):572-576. doi:10.1089/cap.2012.0075
Bachu, Kalyan1; Godkar, Darshan1 *; Gasparyan, Anna1; Sircar, Padmini1; Yakoby, Mila1; Niranjan, Selvanayagam2. Aripiprazole-Induced Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH). American Journal of Therapeutics: July 2006 - Volume 13 - Issue 4 - p 370-372
Cahaya N, Kristina SA, Widayanti AW, Green J. Interventions to Improve Medication Adherence in People with Schizophrenia: A Systematic Review. Patient Prefer Adherence. 2022;16:2431-2449. Published 2022 Sep 1. doi:10.2147/PPA.S378951
Lin D, Thompson-Leduc P, Ghelerter I, et al. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis. CNS Drugs. 2021;35(5):469-481. Doi:10.1007/s40263-021-00815-y
Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341-356. doi:10.1002/wps.20567
Chiang CY, Lo SC, Beckstead JW, Yang CY. Associations between constipation risk and lifestyle, medication use, and affective symptoms in patients with schizophrenia: a multicenter cross-sectional study. Soc Psychiatry Psychiatr Epidemiol. 2025;60(2):427-440. doi:10.1007/s00127-024-02729-8
Damjanov I. Pathology secrets. 3rd ed, Philadelphia, PA: Mosby/Elsevier; 2009:161–202.
Atallah-Yunes SA, Ready A, Newburger PE. Benign ethnic neutropenia. Blood Rev. 2019;37:100586. doi:10.1016/j.blre.2019.06.003
Shymko G, Grace T, Jolly N, et al. Weight gain and metabolic screening in young people with early psychosis on long acting injectable antipsychotic medication (aripiprazole vs paliperidone). Early Interv Psychiatry. 2021;15(4):787-793. doi:10.1111/eip.13013
DISCLAIMER
The information provided in this course is general in nature, and it is designed solely to provide participants with continuing education credit(s). This course and materials are not meant to substitute for the independent, professional judgment of any participant regarding that participant’s professional practice, including but not limited to patient assessment, diagnosis, treatment, and/or health management. Medical and pharmacy practices, rules, and laws vary from state to state, and this course does not cover the laws of each state; therefore, participants must consult the laws of their state as they relate to their professional practice.
Healthcare professionals must consult their employer, healthcare facility, hospital, or other organization for guidelines, protocols, and procedures to follow. The information provided in this course does not replace those guidelines, protocols, and procedures, but is for academic purposes only, and this course’s limited purpose is for the completion of continuing education credits.
Participants are advised and acknowledge that information related to medications, their administration, dosing, contraindications, adverse reactions, interactions, warnings, precautions, or accepted uses is constantly changing. Any person taking this course understands that such a person must make an independent review of medication information before any patient assessment, diagnosis, treatment and/or health management. Any discussion of off-label use of any medication, device, or procedure is informational only, and such uses are not endorsed hereby.
Nothing contained in this course represents the opinions, views, judgments, or conclusions of RxCe.com LLC. RxCe.com LLC is not liable or responsible to any person for any inaccuracy, error, or omission with respect to this course or course material.
© RxCe.com LLC 2026: All rights reserved. No reproduction of all or part of any content herein is allowed without the prior, written permission of RxCe.com LLC.
RxCe.com
© RxCe.com LLC 2025: All rights reserved.